Liminal BioSciences Pulls Plug On Its Lead Development Program

Liminal BioSciences Inc LMNL will discontinue the development of fezagepras based on results from the Phase 1a single ascending dose (SAD) trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger.
The recommendation to stop the development program for fezagepras was not based on safety concerns.
The Phase 1a SAD trial was designed to provide further data to determine if fezagepras is worth developing for one of the many potential indications where nitrogen scavenging is beneficial.
Related: Liminal BioSciences Outlines Plans To Further Develop Its Lead Compound.
The study was started in May.
"We have come to this decisive, data-driven conclusion early in Q3 in line with previously issued guidance," stated Bruce Pritchard, CEO.
"This allows us to focus our resources on our preclinical development programs. We look forward to updating the market on our expected milestones for our GPR84 and OXER1 antagonists' preclinical candidates targeting inflammatory, metabolic, and fibrotic conditions. In addition to these programs, we continue to explore other development opportunities to add to our pipeline," Pritchard added.
According to the company's website, Liminal is working on two preclinical candidates.
Price Action: LMNL shares closed at $0.58 on Thursday.